Discovery STREAM

  1. BoB@JPM: Gene Writing With Tessera's Michael Severino, M.D. 2/26/2023

    Flagship Pioneering plucked Michael Severino, M.D. away from AbbVie to run point at Tessera, a startup it's backed to pioneer a new category of genetic medicine it calls gene writing. The Business of Biotech caught up with Severino at the JP Morgan Healthcare Conference in San Francisco last month. We learned what lured him away from leadership positions at Merck, Amgen, and AbbVie, how gene writing differs from gene therapy and gene editing, why the team at Tessera believes its technologies can write and rewrite DNA at the scales necessary to cure most genetic diseases, and where he plans to take the company from here. 

  2. LC/MS Method For Measurement In Human Plasma 2/17/2025

    According to the researchers, this plasma-based measurement has the potential to serve as a critical pharmacodynamic biomarker, facilitating the assessment of novel therapeutic approaches.

  3. Bio Career Moves With Codagenix's Johanna Kaufmann, Ph.D. 10/11/2023

    On this week's episode of the Business of Biotech, Dr. Johanna Kaufmann gives us an intimate retrospective on her career to date, sharing stories about her rapid ascension from Scientist 1 to executive leadership. We dig into her wild ride through M&A, her time at GSK, and the professional and personal development regimens she subscribes to.

  4. Saudi Arabia Government Leaders Discuss Agile Manufacturing Beyond Borders 10/23/2022

    Learn how government leaders in Saudi Arabia planned for biopharma resilience beyond borders and used agile manufacturing to prepare for the unknown.

  5. Tissue Adenosine Distribution-Guided Gene Selection 2/17/2025

    Unlike conventional predictive biomarkers, which often focus on isolated molecular markers, this strategy integrates spatial metabolomics and genomics, providing a multidimensional perspective.

  6. Pragmatic Computational Biology with Andrew Satz 9/20/2023

    This week's guest on the Business of Biotech, EVQLV's Andrew Satz, says AI and ML in biopharma are like sex in high school. "Many of the people who say they're doing it really aren't, and the one who really are aren't talking about it," he says. So, when it comes to the computational biology buzz, what’s real? What’s hype? What’s yielding benefit and what’s merely vaporware?

  7. STUDIUS™ & ICON™: Data-Driven Workflow For The Development Of Modern Cell-Based Therapies 2/28/2022

    Learn how these two new products work to provide a new data-driven workflow for the development of modern cell-based therapies.

  8. Bio & The Business Of Aging with Life Biosciences' Jerry McLaughlin 9/7/2023

    Core to the clinical-stage biopharma Life Biosciences belief set is that "contrary to popular belief, aging is not caused by random wear and tear, but instead is caused by a discrete set of biological mechanisms that can be targeted therapeutically.”